Trials / Completed
CompletedNCT01604291
An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C
Multi-Center, Non-Interventional Study, on the Efficacy of Dual and Triple Therapies Based on Pegylated Interferon Alfa-2a for the Treatment of Chronic Hepatitis C Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 991 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This multi-center, observational study will evaluate the efficacy and safety of dual and triple therapies based on Pegasys (peginterferon alfa-2a) in patients with chronic hepatitis C. Patients receiving treatment with either Pegasys plus ribavirin or Pegasys plus ribavirin plus telaprevir/boceprevir will be observed for the duration of their treatment and for up to 24 weeks of follow-up.
Conditions
Timeline
- Start date
- 2012-05-28
- Primary completion
- 2016-02-10
- Completion
- 2016-02-10
- First posted
- 2012-05-23
- Last updated
- 2019-03-14
- Results posted
- 2019-03-14
Locations
21 sites across 1 country: Israel
Source: ClinicalTrials.gov record NCT01604291. Inclusion in this directory is not an endorsement.